文献速递糖尿病

2型糖尿病患者丙型肝炎病毒清除后血糖控制改善

Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus.
PubMed 文献 · Diabetes Care · 2017-06-28

研究纳入2435例接受无干扰素无利巴韦林直接抗病毒药物治疗丙型肝炎病毒的糖尿病患者,比较获得持续病毒学应答者与未获得者的血糖控制变化。基线HbA1c升高的患者中,获得持续病毒学应答者HbA1c下降0.98%,治疗失败者下降0.65%(校正均值差0.34,P=0.02);获得持续病毒学应答者胰岛素使用从41.3%降至38%,治疗失败者从49.8%升至51%。

要点

  • 基线HbA1c升高的糖尿病患者中,获得持续病毒学应答者HbA1c下降0.98%,治疗失败者下降0.65%。
  • 获得持续病毒学应答者胰岛素使用从41.3%降至38%,治疗失败者从49.8%升至51%。
  • 直接抗病毒药物清除丙型肝炎病毒与糖尿病患者血糖控制改善相关。

核心结论

  • 直接抗病毒药物清除丙型肝炎病毒与糖尿病患者血糖控制改善相关,表现为平均HbA1c下降和胰岛素使用减少。

研究设计与样本

  • 研究纳入2435例在 national Veterans Affairs health care system 接受无干扰素无利巴韦林直接抗病毒药物治疗丙型肝炎病毒的糖尿病患者。
  • 比较获得持续病毒学应答者与未获得者抗病毒治疗前后1年平均HbA1c水平及抗糖尿病药物使用变化。

主要发现

  • 基线HbA1c升高的患者中,获得持续病毒学应答者HbA1c下降0.98%,治疗失败者下降0.65%(校正均值差0.34,P=0.02)。
  • 获得持续病毒学应答者抗糖尿病药物使用减少多于治疗失败者,尤其是胰岛素使用从41.3%降至38%,而治疗失败者从49.8%升至51%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatitis C virus (HCV) infection is associated with diabetes and may worsen glycemic control in patients with diabetes. We aimed to investigate whether eradication of HCV infection with direct-acting antiviral (DAA) agents is associated with improved glycemic control in patients with diabetes. RESEARCH DESIGN AND METHODS: We identified 2,435 patients with diabetes who underwent interferon-free and ribavirin-free DAA-based antiviral treatment for HCV in the national Veterans Affairs health care system. Changes in average hemoglobin A1c (HbA1c) level and use of antidiabetic medications 1 year before and after antiviral treatment were compared between patients who achieved sustained virologic response (SVR) and those who did not. RESULTS: Among patients with elevated baseline HbA1c, the drop in HbA1c associated with antiviral treatment was greater in those who achieved SVR (0.98%) than in those who sustained treatment failure (0.65%) (adjusted mean difference 0.34, P = 0.02). Use of antidiabetic medications decreased more in patients who achieved SVR than in those who sustained treatment failure, especially for the use of insulin, which dropped significantly from 41.3% to 38% in patients achieving SVR compared with a slight increase from 49.8% to 51% in those who sustained treatment failure. CONCLUSIONS: DAA-based eradication of HCV is associated with improved glycemic control in patients with diabetes as evidenced by decreased mean HbA1c and decreased insulin use. These endocrine benefits of SVR provide additional justification for considering antiviral treatment in all patients with diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hum J, Jou JH, Green PK, et al. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care. 2017. PMID: 28659309. doi:10.2337/dc17-0485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。